{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T12:42:05Z","timestamp":1790080925867,"version":"4.0.1"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2020,2,1]]},"DOI":"10.1001\/jamaoncol.2019.3994","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T16:31:37Z","timestamp":1576773097000},"page":"248","source":"Crossref","is-referenced-by-count":53,"title":["Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia"],"prefix":"10.1001","volume":"6","author":[{"given":"Steven T.","family":"Bird","sequence":"first","affiliation":[{"name":"Office of Pharmacovigilance and Epidemiology, Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Tian","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance and Epidemiology, Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Flowers","sequence":"additional","affiliation":[{"name":"Acumen LLC, Burlingame, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Przepiorka","sequence":"additional","affiliation":[{"name":"Office of Hematology and Oncology Products, Division of Hematology Products, Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Wang","sequence":"additional","affiliation":[{"name":"Acumen LLC, Burlingame, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hyun","family":"Jung","sequence":"additional","affiliation":[{"name":"Division of Biometrics, Office of Biostatistics, Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zebulin","family":"Kessler","sequence":"additional","affiliation":[{"name":"Acumen LLC, Burlingame, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Woods","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance and Epidemiology, Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Kim","sequence":"additional","affiliation":[{"name":"Acumen LLC, Burlingame, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry W.","family":"Miller","sequence":"additional","affiliation":[{"name":"Office of Hematology and Oncology Products, Division of Hematology Products, Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wernecke","sequence":"additional","affiliation":[{"name":"Acumen LLC, Burlingame, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Biometrics, Office of Biostatistics, Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"McKean","sequence":"additional","affiliation":[{"name":"Acumen LLC, Burlingame, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Gelperin","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance and Epidemiology, Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"MaCurdy","sequence":"additional","affiliation":[{"name":"Acumen LLC, Burlingame, California"},{"name":"Department of Economics, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Kelman","sequence":"additional","affiliation":[{"name":"Centers for Medicare & Medicaid Services, Woodlawn, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Graham","sequence":"additional","affiliation":[{"name":"Office of Pharmacovigilance and Epidemiology, Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"11","key":"coi190082r5","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma.","volume":"370","author":"Gopal","year":"2014","journal-title":"N Engl J Med"},{"issue":"11","key":"coi190082r6","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"coi190082r8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"6","key":"coi190082r9","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"1","key":"coi190082r10","first-page":"45","article-title":"The Social Security Administration\u2019s Death Master File: the completeness of death reporting at older ages.","volume":"64","author":"Hill","year":"2001-2002-2002","journal-title":"Soc Secur Bull"},{"issue":"33","key":"coi190082r13","doi-asserted-by":"publisher","first-page":"3745","DOI":"10.1200\/JCO.2017.73.4186","article-title":"Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015.","volume":"35","author":"Jin","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16","key":"coi190082r14","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1056\/NEJMp1615879","article-title":"Reevaluating eligibility criteria \u2013 balancing patient protection and participation in oncology trials.","volume":"376","author":"Beaver","year":"2017","journal-title":"N Engl J Med"},{"key":"coi190082r16","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1182\/blood-2018-99-110655","article-title":"Survival outcomes following idelalisib interruption in the treatment of relapsed or refractory indolent Non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukemia.","volume":"132","author":"Ma","year":"2018","journal-title":"Blood"},{"issue":"5","key":"coi190082r18","doi-asserted-by":"publisher","first-page":"662","DOI":"10.6004\/jnccn.2015.0197","article-title":"Updates to the management of chronic lymphocytic leukemia.","volume":"13","author":"Wierda","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"15","key":"coi190082r19","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1200\/jco.2013.31.15_suppl.7003","article-title":"Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kd, in patients with relapsed or refractory CLL abstract].","volume":"31","author":"Brown","year":"2013","journal-title":"J Clin Oncol"},{"key":"coi190082r20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1986.1986","article-title":"A phase 2 study of idelalisib monotherapy in previously untreated patients =65 years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).","author":"Zelenetz","year":"2014","journal-title":"Blood"},{"issue":"15","key":"coi190082r22","article-title":"A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas","volume":"31","author":"Leonard","year":"2013","journal-title":"J Clin Oncol"},{"key":"coi190082r1","year":"2018"},{"key":"coi190082r2","unstructured":"U.S. Food and Drug Administration. FDA alerts healthcare professionals about clinical trials with Zydelig (idelalisib) in combination with other cancer medications. https:\/\/www.fda.gov\/ Drugs\/DrugSafety\/ucm490618.htm?source=govdelivery&utm_medium=email&utm_source=govdelivery. Accessed May 10, 2019."},{"key":"coi190082r3","unstructured":"Gilead Sciences. Dear Health Care Provider Letter; decreased overall survival and increased risk of serious infections in patients receiving Zydelig (idelalisib). http:\/\/cllsociety.org\/docs\/ Zydelig%20Safety%20Update.pdf. Accessed May 10, 2019."},{"key":"coi190082r4","unstructured":"European Medicines Agency. EMA recommends new safety measures for Zydelig. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2016\/03\/news_detail_002490.jsp&mid=WC0b01ac058004d5c1. Accessed May 10, 2019."},{"key":"coi190082r7","unstructured":"International Council for harmonization of Technical Requirements for Pharmaceuticals for Human Use. MedDRA: Medical Dictionary for Regulatory Activities. https:\/\/www.meddra.org\/. Accessed May 10, 2019."},{"key":"coi190082r11","unstructured":"U.S. Food and Drug Administration. What is a serious adverse event? https:\/\/www.fda.gov\/ Safety\/MedWatch\/HowToReport\/ucm053087.htm. Accessed May 10, 2019."},{"key":"coi190082r12","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm. Accessed May 10, 2019."},{"key":"coi190082r15","unstructured":"Food and Drug Administration. Cancer clinical trial eligibility criteria: patients with HIV, hepatitis B, or hepatitis C virus infections guidance to industry. https:\/\/www.fda.gov\/down loads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM633136.pdf. Accessed May 10, 2019."},{"key":"coi190082r17","unstructured":"U.S. National Library of Medicine. Dose optimization study of idelalisib in follicular lymphoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02536300. Accessed May 10, 2019."},{"key":"coi190082r21","unstructured":"U.S. National Library of Medicine. Efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent Non-Hodgkin lymphomas. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01732913. Accessed May 10, 2019."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2757394\/jamaoncology_bird_2019_oi_190082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T10:29:31Z","timestamp":1613212171000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2757394"}},"subtitle":["A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries"],"short-title":[],"issued":{"date-parts":[[2020,2,1]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2019.3994","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,1]]}}}